TRACON Pharmaceuticals Inc. (NASDAQ:TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, has said that it will host a key opinion leader (KOL) webinar on envafolimab for the treatment of sarcoma on Friday, July 17, 2020, at 11.00am Eastern Time.
The webinar will feature a presentation by Robert Maki, MD, PhD, of the University of Pennsylvania School of Medicine, who will discuss the current treatment landscape and unmet medical need in treating patients with sarcoma. He will be available to answer questions at the conclusion of the event.
READ: TRACON Pharmaceuticals says separate study buoys potential of envafolimab combination to treat sarcoma
Dr Maki is a graduate of Cornell University Medical College, and has a PhD. in Immunology from Cornell University Graduate School of Medical Sciences. He completed his internship and residency at Brigham and Women’s Hospital and fellowship in medical oncology at the Dana Farber Cancer Institute.
His expertise includes the more than 70 types of bone and soft tissue sarcomas, and he is the co-author of 'Management of Soft Tissue Sarcoma', from Springer Books.
TRACON's chief executive officer, Charles Theuer, MD, PhD, will also provide an update on envafolimab, the company’s lead product candidate for treating patients with sarcoma. Envafolimab is a novel, single-domain antibody against PD-L1 that is administered by subcutaneous injection without the need for an adjuvant.
It is currently being studied in China in a Phase 2 registration trial as a single agent in MSI-H/dMMR colorectal cancer patients, in combination with gemcitabine and oxaliplatin in a Phase 3 registration trial in biliary tract cancer, as well as in several Phase 1 trials in the US and Japan.
Having agreed with the US Food and Drug Administration (FDA) on trial design, TRACON intends to initiate the ENVASARC pivotal study of envafolimab in the sarcoma subtypes of undifferentiated pleomorphic sarcoma and myxofibrosarcoma in the second half of 2020.
Contact the author at [email protected]